Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
- PMID: 8380242
- DOI: 10.7326/0003-4819-118-3-199302010-00003
Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
Abstract
Objective: To study the efficacy and toxicity of ganciclovir prophylaxis given at engraftment to cytomegalovirus (CMV)-seropositive, allogeneic bone marrow transplant recipients.
Design: A double-blind, placebo-controlled study.
Setting: The Fred Hutchinson Cancer Research Center, a referral marrow transplant center.
Patients: This study was conducted from November 1990 to August 1991. Ninety-three CMV-seropositive patients were entered into the study before marrow transplant, with 64 patients randomized to receive the study drug after marrow engraftment. Thirty-one patients received placebo, and 33 received ganciclovir. The dose was 5 mg/kg body weight administered intravenously twice daily for 5 days, followed by once daily until day 100 after transplant.
Measurements: Outcome variables measured were CMV infection, monitored by weekly cultures, and neutropenia, defined as an absolute neutrophil count of 0.750 x 10(-9)/L for 2 consecutive days. Cytomegalovirus disease and mortality were secondary end points.
Results: Fourteen (45%) placebo recipients developed CMV infection in the first 100 days after marrow transplant compared with one (3%) ganciclovir recipient (P < 0.001). Nine (29%) placebo recipients developed CMV disease compared with no cases in the ganciclovir group during the first 100 days (P < 0.001). Neutropenia occurred in 10 ganciclovir recipients (30%) compared with no cases in the placebo group during the period of observation (P = 0.001). In a separate analysis, patients on ganciclovir who became neutropenic were at greater risk (relative risk, 4.3; P = 0.02) for bacterial infection. Mortality between the two study groups did not differ statistically at 100 and 180 days.
Conclusion: Ganciclovir given prophylactically after engraftment is effective in suppressing CMV infection and disease. Neutropenia is an important side effect of ganciclovir use and is associated with an increased risk for bacterial infection.
Similar articles
-
Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial.Ann Intern Med. 1993 Feb 1;118(3):179-84. doi: 10.7326/0003-4819-118-3-199302010-00004. Ann Intern Med. 1993. PMID: 8380243 Clinical Trial.
-
Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.N Engl J Med. 1991 Dec 5;325(23):1601-7. doi: 10.1056/NEJM199112053252303. N Engl J Med. 1991. PMID: 1658652 Clinical Trial.
-
Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.Blood. 1996 Nov 15;88(10):4063-71. Blood. 1996. PMID: 8916975 Clinical Trial.
-
Strategies for the prevention of cytomegalovirus disease after marrow transplantation.Clin Infect Dis. 1994 Aug;19(2):287-98. doi: 10.1093/clinids/19.2.287. Clin Infect Dis. 1994. PMID: 7986901 Review.
-
Cytomegalovirus prophylaxis and treatment following bone marrow transplantation.Ann Pharmacother. 1996 Nov;30(11):1277-90. doi: 10.1177/106002809603001113. Ann Pharmacother. 1996. PMID: 8913411 Review.
Cited by
-
A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation.BMC Infect Dis. 2006 Nov 21;6:167. doi: 10.1186/1471-2334-6-167. BMC Infect Dis. 2006. PMID: 17118205 Free PMC article.
-
Quantification of human cytomegalovirus DNA in bone marrow transplant recipients by real-time PCR.J Clin Microbiol. 2001 Dec;39(12):4362-9. doi: 10.1128/JCM.39.12.4362-4369.2001. J Clin Microbiol. 2001. PMID: 11724846 Free PMC article.
-
Separating antiviral and GVHD activities of donor T cells prior to bone marrow transplantation.Immunol Res. 2004;29(1-3):209-18. doi: 10.1385/IR:29:1-3:209. Immunol Res. 2004. PMID: 15181283 Review.
-
A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.Clin Infect Dis. 2020 Apr 10;70(8):1525-1533. doi: 10.1093/cid/ciz490. Clin Infect Dis. 2020. PMID: 31179485 Free PMC article. Clinical Trial.
-
Gene expression profiles of various cytokines in mesenchymal stem cells derived from umbilical cord tissue and bone marrow following infection with human cytomegalovirus.Cell Mol Biol Lett. 2014 Mar;19(1):140-57. doi: 10.2478/s11658-014-0187-3. Epub 2014 Feb 25. Cell Mol Biol Lett. 2014. PMID: 24569981 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical